Aptamer Group PLC Contract wins (5677J)
August 17 2023 - 1:00AM
UK Regulatory
TIDMAPTA
RNS Number : 5677J
Aptamer Group PLC
17 August 2023
17 August 2023
Aptamer Group plc
Contract wins
Aptamer Group plc (AIM: APTA), the developer of novel Optimer
(R) binders to enable innovation in the life sciences industry,
today announces signing of two new contracts with a top five pharma
partner valued up to GBP219,000.
These two contracts represent further conversion of the sales
pipeline announced previously. The final value to be recognised as
revenue for these new contracts will be subject to scientific and
commercial attrition as the contracts progress, which is scheduled
to be completed over the course of the current financial year.
The first contract is for the development of an Optimer pair to
a neurodegenerative biomarker for use in an immunoassay platform.
The second contract is a follow-on contract for the final stage of
Optimer development to a neuronal protein target for
immunohistochemistry (IHC), following positive results in the
earlier stages of Optimer development. This builds on the adoption
of our Optimer-Fc platform for use in automated IHC workflows.
Optimer binders are being sought as alternatives to traditional
antibodies for analytical assays to enable increased accuracy and
selectivity in the detection of validated biomarkers, while the
extended target range of Optimer binders compared with antibodies
enables the generation of reagents to novel biomarkers.
Dr Rob Quinn, CEO of Aptamer Group, said: "I am pleased to be
able to extend our partnership with this top five pharma partner.
These two projects are further evidence of the need for Optimer
binders to meet challenging requirements for use in real-world
applications when, to date, antibodies have been unable to provide
a satisfactory solution, such as IHC. Building awareness and
adoption of Optimer technology by such partners is key to allowing
us to deliver on our strategy of executing therapeutic, diagnostic,
and bioprocessing licensing deals."
- ENDS -
For further information, please contact:
Aptamer Group plc
Dr Rob Quinn +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Mark Brady / Adam Dawes +44 (0) 20 3368 3550
-----------------------
T urner Pope I nvestments (TPI) Limited
- B roker
J ames Pope +44 (0) 20 36 57 0 073
-----------------------
Consilium Strategic Communications
Matthew Neal / Lucy Featherstone
aptamergroup@consilium-comms.com +44 (0) 20 3709 5700
-----------------------
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK
domestic law by virtue of the European Union (Withdrawal) Act
2018.
About Aptamer Group plc
Aptamer develops custom affinity binders through its proprietary
Optimer (R) platform to enable new approaches in therapeutics,
diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life
science researchers and developers through the use of its
proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global affinity ligand
market is currently worth over $170 billion. Optimer binders are
engineered to address many of the issues found with alternative
affinity molecules, such as antibodies, and offer new, innovative
solutions to bioprocessing, diagnostic and pharmaceutical
scientists.
Aptamer has successfully delivered projects for global pharma
companies, diagnostic development companies, and research
institutes covering a range of targets and applications with the
objective of establishing royalty-bearing licenses. Through the
unique Optimer technology and processes, scientists and
collaborators can make faster, more informed decisions that support
discovery and development across the Life Sciences.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUNRUROBUWAUR
(END) Dow Jones Newswires
August 17, 2023 02:00 ET (06:00 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024